HLA class I and advanced melanoma in Israeli Jews
- J Schachter
- T Klein
- B Klein
- A Adler
Affiliations: RABIN MED CTR,TISSUE TYPING LAB,IL-49100 PETAH TIQWA,ISRAEL. RABIN MED CTR,ONCOL UNIT,IL-49100 PETAH TIQWA,ISRAEL. TEL AVIV UNIV,SACKLER FAC MED,IL-69978 TEL AVIV,ISRAEL.
- Published online on: March 1, 1997 https://doi.org/10.3892/ijo.10.3.645
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
KLA class I antigen was studied in Jewish melanoma patients. The frequency of HLA A24, A26 and B38 was significantly higher in the melanoma patients (34.7%, 39.1% and 38.6%, respectively) compared to controls (16.6%, 18.5% and 20.6%, respectively) (p<0.005). HLA A24 antigen was significantly higher in the metastatic patients (44.8%) compared to the non-metastatic (11.1%) (p<0.001). The frequency of this antigen was also higher in the patients with recurrent disease (16.6%) than in the high risk patients with no recurrence (11.1%). HLA class I and A24 may play a role in the biologic behavior of malignant melanoma.